Author

Amanda Tracz

Roswell Park Comprehensive Cancer CenterORCID 0009-0003-2335-7571Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Assay:flow cytometry· 1

Frequent Co-Authors

Dean G. TangiD· 2 shared Gurkamal S. ChattaiD· 2 shared Igor J. PuzanoviD· 2 shared Wen Jess LiiD· 2 shared Xiaozhuo LiuiD· 2 shared Ahmed M. Abdelaal· 1 shared Andrea L. KasinskiiD· 1 shared Anmbreen JamrozeiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Dean G. TangORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologySignal Transduction and Targeted TherapyPeer-reviewedMay 1, 2026

Cell-resolved high-dimensional imaging analysis, therapeutic modeling, and a Phase Ib clinical study validate BCL-2 as a target across heterogeneous CRPC subtypes

Anmbreen Jamroze, Xiaozhuo Liu, Surui Hou…·Dean G. Tang

This study validates BCL-2 as a therapeutic target in CRPC by showing its upregulation under AR inhibition and demonstrating efficacy of BCL-2 inhibitors in preclinical and clinical models.

1 citation

humanimaging

𝕏 PostBluesky

Cancer BiologyInternational Journal of Molecular SciencesPeer-reviewedFeb 9, 2024

Developing folate-conjugated miR-34a therapeutic for prostate cancer treatment: Challenges and promises

Wen Li, Yunfei Wang, Xiaozhuo Liu…·Dean G. Tang

This study evaluates folate-conjugated miR-34a as a potential prostate cancer therapeutic, finding limited efficacy due to low FOLR1 expression in prostate cancer cells.

33 citationstop 4%

humanexperimental assay

𝕏 PostBluesky